ABSTRACT
Abnormal localization of immature myeloid precursor (ALIP) 45, 52,159
Absolute neutrophil count (ANC) 75,109,179,180
Acanthocyte 4,18 Acute basophilic leukemia 11,13,
96,99 Acute lymphoblastic leukemia 8,11,
20,24,89,113,159,161 Acute megakaryoblastic leukemia
FAB-M7 30,32,90,96,98, 103,105,106,111
Acute monoblastic leukemia FAB-M5 94,95,101,102,110
Acute myeloid leukemia (AML) 9, 11,13,21,22,30,36-38,48, 59,60,62,64,66,67,69-71,74, 80-83, 85,88-110,112-116,119, 120,159,161,176
minimally differentiated FAB-M0 91,92
with inv(3)(q21;q26.2) or t(3;3) (q21;q26.2); RPN1-EVI1 103
with inv(l6)(pl3.1;q22) or t(16;l6)(pl3.1;q22); СВҒВ/ MYH11 71,101
with maturation FAB -M2 90,91, 93.101.102.104
with mutated СЕВРА 36, 38, 100.104
with myelodysplastic syndrome (MDS)-related change 90, 98.100.102.104
without maturation FAB -M 1 91, 92,101,102,104
with recurrent chromosomal abnormality 90,99
with t(l;22)(pl3 ;q l3), RBM15-MKL1 103
with t(6;9) (p23;q34);DEK-NUP214 36,48,103
with t(8;21)(q22;q22); RUNX1 -RUNX1T 1 101
with t(9;l I)(p22;q23): MLLT3-MLL 36,102
not otherwise specified AML, NOS 90,99
Acute panmyelosis with myelofibrosis 66, 96,100
Acute promyelocytic leukemia FAB-M3 30,89,101-103,111, 112
Adult T-cell leukemia/lymphoma (ATLL) 9,123,133-135
Aggressive NK (natural killer)-cell leukemia 123,132,133
Aggressive systemic mastocytosis (ASM) 75,76
Alder-Reilly anomaly 7 ALK-1 32 Alloimmune thrombocytopenia 177 Alpha naphthyl butyrate esterase 90 Amyloidosis 138,143,145,146,150 Anaplastic large cell lymphoma
(ALCL) 9,15,20-22,32,37, 153,156-159,162
Anemia 3-7,10-12,29,43,45, 46, 50, 56,65-67,73,80-84, 88,96,108,109,113,124, 125,127-132,138,139,141, 145-148,161,165-177,179, 180,182,183
Anemia o f chronic disease 3,168, 169,172,173
Anisocytosis 2,3,175,182 AnnexinAl 22,27 Anti-CD4la autoantibody 177 Aplastic anemia 45,108,128,129,
166,168,179,182 Atypical chronic myeloid leukemia
(aCML) 81,82,86 Atypical lymphocyte (ATL) 8,9,
122,133,156,157,179 Auer rod 8,13,45,46,47,49,81,
83,88,89,91,101,102,109, 110,114
Autoimmune gastritis 175
B12 3 ,44,45,49,57,86,96,166, 168-170,174-176
Basophilia 6,11,12, 56, 59,62,63, 68,72,80-83,99,103,105
Basophilic stippling 6,19,173-175, 182
В-cell prolymphocytic leukemia (B-PLL) 123,126-128,134
Bcl-2 22,27,28,32,158,160 Bcl-6 32,158 BCR/ABL1 35 Bidonai acute leukemia 3 1 Biphenotypic leukemia 30 Bite cell 4,18 Blastic plasmacytoid dendritic cell
(BPDC) neoplasm 90,106, 107
BM recovery following myelosuppression 109
Bone marrow (BM) iron stores 171, 174
Bone Marrow Report Template 1 Burkitt lymphoma 24,27,28,37,
115,156,160,163 Burr cell 4
Causes of reactive thrombocytosis 68,69
CD (cluster designation) 9,20-24, 26-30,32,41,45,49,74,76,87, 89,92-103,106-109,115-120, 125-132,134,138-144,148, 154,156,158-162,164
C D la 21,24,29,120,130 CD2 21,24,29,30,74,76,89,
92,102,107,120,130,132 CD2 and CD25 on neoplastic
mast cell 24,74,76 CD3 21,24,29, 30, 32, 89,120,
130-132,134,158,159 CD4 9 ,21,24,26,29,30,32,89,
94,95,107,120,130-132, 134.143.154
CD5 21,24,26-29,89,120,125, 128-130,148,154,158
CD7 21,24,26,29,30,89,92-94, 106.107.120.130.154
CD8 21,24,26,29,32,120, 130-132,134,154
CD10 21,24,27-30,116-118, 120,129,140,148,154,158
C D llb 21,30,89,93-95,99,131 CD 11c 21,24,27,28,30,89,94,
95,125,129 CD 13 21,24,30,89,92-95,98,
99,101,106,116,117,120 CD 14 21,24,30,74,89,94,95 CD15 21,74,89,93-95,102,
116,117,161,162 CD16 21,29,30,74,89,94,132 CD 19 21,24,26-28,30,89,92,
101,115-117,125,127,129, 140.142.143.148
CD20 21,24,26-29,32,45,74, 89,109,117,125,127,129, 140,142,148,158,159,161
CD21 21 CD22 21,27,30,89,116,125,
127.129.148
CD23 21,24,26-28,125,128, 129.148.154.158
CD25 21,24,27,28,74,76,87, 129.134.161
CD30 21,32,134,156,158,159, 161,162,164
CD33 21,24,30,74,89,92-95, 98,99,101,102,106,107, 116,117,120
CD34 21,24,28,30,32,41, 89.92-95,98,99,102,103, 106-109,116,117,119
CD38 21, 26,27,92,107,116, 126,138,140,144,148
CD41 21, ЗО, 89,96-98,100, 106,108
CD43 22,27,107,158 CD45 22-24, ЗО, 74,89,97,98,
106,116 CD56 22,29,101,102,106,107,
132,140 CD57 22,131,132 C D 61 22, ЗО, 32,49,89,96-98,
100,106,108 CD64 22,24,30,89,94,95 CD79a 22,32,89,116,120,125,
127.129.140.158 CD79b 22,127,129 CD99 22,32 CD 103 22,24,27,28,129 CD 117 22,24, ЗО, 32,74,76,
89.92-95,99,102,107,108, 120.161
CD 138 22,138-142,144 Chediak-Higashi syndrome 7,180,
181 Chloroacetate esterase (CAE) 74,
89-94,97 Chromosomal abnormalities associated
with MDS, in decreasing order of frequency 48
Chronic eosinophilic leukemia (CEL), not otherwise categorized (NOC) 70,71
Chronic lymphocytic leukemia (CLL) 8,24,26,115,122,123, 127,142,147,148
Chronic myelogenous leukemia, accelerated phase (CML-AP) 54, 56, 57
Chronic myelogenous leukemia, blast phase (CML-BP) 56-59
Chronic myelogenous leukemia, chronic phase (CML-CP) 56
Chronic myelomonocytic leukemia (CMML) 9,59,79-81,85,86
Clinical and morphological differences between PV and secondary erythrocytosis 63
Common acute lymphoblastic leukemia antigen (CALLA), see also CD10 21,28
Common precursor B-ALL 116,117 Complete blood count (CBC) 1,2,
17,26,35,43, 55,64,128,129, 176
Cutaneous mastocytosis 72 Cyclic neutropenia 180,181 Cyclin D 1 (bel-1) 22,27,28,37,
125,127-129,154,157,160, 162,164
Cytokeratin cocktail 32 Cytoplasmic vacuolization 6,10, 19,
43,44,72,107,115
D DBA.44 22,129 Diffuse large В-cell lymphoma
(DLBCL) 125,152,153, 156-160,162,163
Disseminated intravascular coagulation (DIC) 4, 5,30,88, 89,102,113,117,167,177,179
Döhle body 6,7, 59 Downey cell 19 Dual esterase 89,93 Dutcherbody 139,140,148,149
Elliptocyte 4,172 Eosinophilia 10,11,35, 56,59,62,
63,70-72,75,76,81-83,86, 87, 101,104,111,115,119,133
Erythroid dysplasia 43,46, 80,105 Erythroid leukemia 30,95-97,105,
110, 111 Erythroleukemia FAB-M6 95,97,
168 Erythropoietin (EPO) level 54, 55,
59,61-64,67,68,173 Essential thrombocythemia (ET)
55-57, 59,60,62,65-69,71,76, 78
Estrogen receptor 32 Extracutaneous mastocytoma 76
F Factor 8 32 Ferritin 69,170-174 Fibroblast growth factor receptor 1
(FGFR1) 35,60,70-72,76,81, 82,84,86,87
Flame cell 140,149 FLT3 mutation 36, 38,100,102,
104 FMC7 24,125,127,129 Folate 3,44,45,96,166,168,169,
174-176,181 Follicular lymphoma 1,17,24,27,
32,129,142,147,148,152-154, 157,163
G Giant platelet 12,13,178,183 Granulocytic dysplasia 8,13,15,45,
46,49,53, 57,60,62,63,65,67, 68,77, 80-83,88,90,96,101, 182
Hairy cell leukemia (HCL) 9,22, 24,25,27,28,32,45,66,74, 109,122,123,128-130,134, 135,158,180,181
Heavy chain deposition disease 147 HELLP (hemolysis, elevated liver
enzymes and low platelets) syndrome 177
Hematogone 22,28,29,49,109, 114,168
Hemoglobin E (Hgb E) 166,172,173 Hemolytic uremic syndrome (HUS)
4,5,167,177,179 Heparin-induced thrombocytopenia
(HIT) 177 HLA-DR 22,24,30,89,92-94,98,
99,102,106,115-117 Hodgkin lymphoma (HL) 10,11,
25,26,66,124,125,151,152, 154,161,162,164,172
Homocysteine 175 Howell-Jolly body 6,19,175 Human T-lymphotrophic virus, type
1 (HTLV-1) 130,133,134 Hyperchromasia 119,132 Hyperdiploidy 37,118,143 Hypereosinophilic syndrome 11, 53,
70,71,115 Hypersplenism 44,75,179 Hypochromic cell 3,68,174 Hypodiploidy 118 Hypogammaglobulinemia 125,136 Hypoplastic myelodysplasia 45
I Idiopathic thrombocytopenic purpura
(ITP) 10,13,44,161,179 Immune thrombocytopenia 124,177 Indolent large granular NK-cell
(natural killer) lymphoproliferative disorder 123
Indolent myeloma 145 Indolent systemic mastocytosis (ISM)
75,76 Infectious lymphocytosis 8,9 Infectious mononucleosis 8, 9 Intertrabecular involvement 45,134,
153,157,162 Intrasinusoidal 66,153,155-159 Iron deficiency anemia 165,
168-174,182
J Janus kinase 2 (JAK2) 35, 36, 38,
54-56,60-65,67,69 gene mutation V617F 55, 56,62
Juvenile myelomonocytic leukiemia (JMML) 82-84
K Kostman syndrome 180,181
L Large platelet 1,3,177 Leukemoid reaction 32, 57-59 Leukoerythroblastosis 8, 55,62,65,
67,68,139 Light chain gammopathy 136 Low blast-count AML 90,107 Lymphoplasmacytic lymphoma 136,
147.152.154.157.163
M Macrocytic anemia 168 Macro-ovalocyte 3,179 Mantle cell lymphoma 24,27,114,
115.148.154.157.164 Marginal zone lymphoma 27,115,
142,147,152-154,157 MART-1 32,159 Mast cell leukemia 74-76 Mast cell sarcoma 76
Mastocytosis 35,70,72,73,75,76, 86,161
May-Hegglin anomaly 7 M-BCR 55 m-BCR 55 μ-BCR 55 Mean corpuscular hemoglobin
concentration (M CHC) 1,2,17 Mean corpuscular hemoglobin
(MCH) 1 ,2 ,3 ,17 Mean corpuscular volume 2,170 Mean corpuscular volume (MCV) 1,
168.169.174-177,179,182,183 Megaloblastoid 14,43,44, 51 Methylmalonic acid (MMA) 175 Microcytic anemia 80,168,170 Monoclonal gammopathy of
undetermined significance (MGUS) 136,145-147
Monoclonal protein 5,125,126, 130,136,138,139,147,162
Monoclonal spike (M-spike) 136 Monocytosis 9,10,72,79-83 Mott cell 149 MPL W 515K/L 65,67,69 MUM1/Irf4 22 Myelodysplastic/myeloproliferative
neoplasm (MDS/MPN) 54, 60,70,71,79,81,84,104
Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/ MPN, U) 84
Myelodysplastic syndrome (MDS) 3,7 ,13 ,14 ,29 ,30 ,32 ,36 ,38 , 43-49, 54,60,63-66,69-71,74, 79-81,84,85,90,95,97,101, 104,105,108,119,159,170, 171.174-177,180,181
Myelodysplastic syndrome prognostic categories based on cytogenetic abnormality 47
Myelodysplastic syndrome/ myeloproliferative neoplasm, unclassifiable-refractory anemia with ring sideroblasts (MDS/ MPN, U-RARS) 84
Myelodysplastic syndrome, unclassified (MDS, U) 46,47
Myeloid proliferations related to Down syndrome 90,105,106
Myeloid sarcoma 90,101 Myeloperoxidase 30,45,49,74, 89,
90,115,120,142,159 Myelophthisis 13, 55,65,165,166,
174,177 Myeloproliferative neoplasms (MPN)
7,11,12,13,35,38,45,47,53-56, 60,63,66,68,70-72,74,76,77, 79,81,84,87,104,177,179
Myeloproliferative neoplasms (MPNs) in which important information is missing 77
Myeloproliferative neoplasms, unclassifiable (MPN, U) 54, 76, 84
MYH9 disorder 177,178
N
Natural killer (NK) 9,21,22,25,29, 100,103,104,122,123,131-133
Neutropenia 6-8,29,43,46,88,113, 122,124,125,129-132,179-182
Non-myelodysplastic (non-MDS) causes of dysplasia 49
Non-secretory myeloma 144 Nonspecific esterase (NSE) 80,
89-95,98,99,115 Normochromic cell 1, 3, 56,61,68,
124,148,172,174 Normocytic anemia 56,148,168 Nucleophosmin 1 gene (NPM) 20,
37,100,103,104
o Osteosclerotic myeloma 147
P Pappenheimer body 6 Paratrabecular 56,73,74,78,96,124,
147,148,153,156,157,161-163 Peripheral T-cell lymphoma (PTCL),
angioimmunoblastic 157 Peripheral T-cell lymphoma (PTCL),
unspecified 157 Persistent polyclonal В-cell
lymphocytosis 161 Pertussis 8,9 Philadelphia chromosome 35,42,
54-56, 58, 80 Plasma cell leukemia (PCL) 136,
139,145,150 Plasma cell myeloma (PCM) 10,14,
22,66,137-144,148-150,162 Platelet clumping 177,183 Platelet-derived growth factor
receptor A (PDGFRA) 35,60, 70-72,76,81,82,84, 86,87
Platelet-derived growth factor receptor В (PDGFRB) 35,60, 70-72,76,81,82,84,86,87
Platelet satellitosis 180,183 Platelet size 176,178 PML/RARa 31 PML-RARA 36,38,101,102 Poikilocyte 4,18,175 Poikilocytosis 2 ,3 ,67,172 Polycythemia vera (PV) 35, 38,
54-56, 59-66,69,71,76 Post-polycythemia vera myelofibrosis
(post-PVMF) 61-64 Post-treatment bone marrow 109 Precursor В lymphoblastic leukemia/
lymphoma (B-ALL/LBL) 37, 38,113,114
Precursor T lymphoblastic leukemia/ lymphoma (T-ALL/LBL) 29, 113,119
Primary myelofibrosis (PMF) 8, 53, 55,64,96
Prolymphocytic transformation 125, 126,128
Prostatic specific antigen (PSA) 32 Pseudo-Pelger-Huët 45,52,81 Pseudothrombocytopenia 177,178,
183 Pure erythroid leukemia 97 Pure white cell aplasia 179,181
R Reactive lymphoid nodule 160,161 Red blood cell (RBC) 1-6, 8,12,14,
17,43, 55,60-62,64,67,68,80, 82,131,132,137,139,165-175, 182
Red blood cell distribution width (RDW) 1-3,17,43,170, 172-176
Reed-Sternberg cell 21,22,26, 32, 125,159,164
Refractory anemia (RA) 22,46,47, 50.81.84.170
Refractory anemia with ring sideroblast (RARS) 46,47, 84, 85.170
Refractory cytopenia with multilineage dysplasia and ring sideroblast (RCMD-RS) 46
Refractory cytopenia with multilineage dysplasia (RCMD) 46,47
Refractory cytopenia with unilineage dysplasia (RCUD) 46
Refractory neutropenia (RN) 46 Refractory thrombocytopenia (RT)
34-37,46 Reticulin fibrosis 45, 54, 57, 59,62,
65, 67,80,81,103,129,140
Reticulocyte correction factor 169 Reticulocyte production index (RPI)
169 Richter transformation 125 Ring sideroblast 2 ,14,17,43,44,46,
51,66,84,95,97,170 Rouleaux 1,3, 5,17,137,139,148
Schistocyte 4,18,179 Serous atrophy 112 Sickle cell 4 Smoldering myeloma 144,145 Spherocyte 5,18,124 Splenomegaly 29, 53, 56,59,61,
63-68,72,73,75,79,81,84,96, 103,123,125,126,128,131, 142,179
Stomatocyte 5,18 Structural genetic abnormalities in
B-ALL 117 Sudan black B (SBB) 90-94,97-99,
106,115 Synaptophysin 32 Systemic lupus erythematosus 181 Systemic mastocytosis 35,70,72,73,
76, 86,161 Systemic mastocytosis with
associated clonal hematological non-mast cell lineage-disease (SM-AHNMD) 75,76
t( 15; 17)(q22;ql2) 101 Target cell 5,18,173 Tartarate-resistant acid phosphatase
(TRAP) 27,32,128,129 T-cell large granular lymphocytic
leukemia (T-LGL) 29,123, 131,132,135
T-cell lymphoma (TCL) 22, 87, 120,132,153-157,159
T-cell prolymphocytic leukemia (T-PLL) 22,123,130,135
T-cell receptor (TCR) 8,26,29,33, 38.120.123.130-132,134,156, 157.159
T-cell receptor (TCR) gene rearrangement 8, 33,159
T-cell rich diffuse large В-cell lymphoma (TCR-DLBCL) 157
Teardrop cell 5,18, 53, 55,62,65, 67,68,175
Terminal deoxynucleotydyl transferase (TdT) 22,24, 28-30,89,91,92,96-99,106, 107,108,116,117,119,120, 130.159
Therapy-related myeloid neoplasm 90,104,105
Thrombocytopenia 5 ,10,13,43,44, 46, 56, 57,73,80-83,96,113, 124.125.127.130-132,139, 148,161,167,175-180
Thymocyte 21,22,29,120 Toxic granules in neutrophil 6,7,
19, 59 Transferrin receptor level 172
V
V617F mutation see Janus kinase 2 gene mutation V617F
w Waldenstrom’s macroglobulinemia
145,147,152 Wiscott-Aldrich syndrome 178
z ZAP70 22
